Specialty Pharma Journal Specialty, Precision & Technology
GAITHERSBURG, Md. and SAINT-HERBLAIN, France, Nov. 19, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. The highly purified inactivated vaccine candidate, VLA1601, met the study’s primary …
Tag Archives: vaccines
November, 2018
-
8 November
NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells in a Novel Cancer Memory Vaccine Immunotherapy
CULVER CITY, Calif.–(BUSINESS WIRE)–The recent successes of immunotherapy, such as checkpoint inhibition, have spawned a wave of enthusiasm for immuno-oncology. Unfortunately, only a subset of cancer patients respond to checkpoint inhibitor monotherapy, and many of these checkpoint-responsive patients will eventually relapse. In addition, cellular therapy in the form of CAR-T …
October, 2018
-
18 October
AELIX and Gilead Collaborate to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure
BARCELONA, Spain–(BUSINESS WIRE)–AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas …
September, 2018
-
21 September
FDA Grants Breakthrough Therapy Designation to Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and …
August, 2018
-
16 August
BioNTech Enters Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
MAINZ, Germany & NEW YORK–(BUSINESS WIRE)–BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of …
-
16 August
Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
GAITHERSBURG, Md., Aug. 13, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for an all-cash consideration of $270 million. PaxVax is majority owned …
May, 2018
-
4 May
FDA Grants PaxVax Fast Track Designation for its Chikungunya Vaccine
REDWOOD CITY, Calif., May 4, 2018 /PRNewswire/ — PaxVax, a leading independent specialty vaccine company, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its vaccine for the prevention of disease caused by the chikungunya virus. Chikungunya represents a significant public …
-
4 May
Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
CAMBRIDGE, Mass. and KENILWORTH N.J., May 3, 2018 — Moderna Therapeutics and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an expansion of their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including …
July, 2017
-
7 July
Experts Urge Action to Cut Child Deaths from Deadly Lung Virus
Vaccines to combat a virus that can lead to fatal lung infections are urgently needed to help prevent child deaths worldwide, research suggests. Experts report that more than 115,000 children under five are dying each year from complications associated with the infection, called Respiratory Syncytial Virus (RSV). Almost half of …
September, 2016
-
2 September
Takeda to Develop Zika Vaccine with up to $312 Million in Funding from US Government
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that BARDA, the Biomedical Advanced Research and Development Authority, has selected Takeda’s Vaccine Business Unit to develop a vaccine to support the Zika response in the US and affected regions around the world. Initial funding from BARDA, which is …